Tennessee Patent of the Month – July 2024
ProNova Solutions, LLC has secured a patent for their new energy selection system used in compact proton therapy. Their solution uses an achromatic superconducting magnet. This innovation revolutionizes cancer treatment technology by compactly directing high-energy proton beams from accelerators to treatment rooms with unprecedented precision and efficiency.
Traditionally, proton therapy systems faced challenges due to their size and cost, limiting widespread adoption. ProNova’s solution integrates a bidirectional superconducting magnet unit within an outer vacuum chamber, strategically positioned to deflect proton beams towards multiple treatment rooms through distinct beam paths. This versatility allows healthcare providers to optimize treatment delivery without compromising on accuracy or effectiveness.
Key to ProNova’s innovation is the achromatic nature of their magnet assembly. By employing combinations of superconducting dipole and quadrupole magnets along with a centrally located collimator, the system effectively selects and manipulates proton beams based on desired energy levels. This capability is pivotal in tailoring treatment to specific patient needs, ensuring precise targeting of tumors while minimizing damage to healthy tissues.
The compact design of ProNova’s system, enabled by internal collimation and efficient magnet configurations, not only enhances treatment efficacy but also reduces overall project costs and equipment footprint. This innovation marks a significant leap forward in proton therapy technology, making advanced cancer treatment more accessible and practical for healthcare facilities worldwide.
ProNova Solutions has addressed thermal management challenges inherent in such high-tech systems. The integration of multiple cooling paths and heat exchange mechanisms ensures optimal performance and longevity of the superconducting magnets, crucial for maintaining operational efficiency and patient safety.
ProNova’s achromatic superconducting magnet assembly represents a paradigm shift in proton therapy. By combining precision, compactness, and cost-effectiveness, this invention sets a new standard in cancer treatment technology, promising improved outcomes and broader patient access to cutting-edge medical care.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
